NEWSROOM

Perspectives on IP strategy, portfolio development, and the factors that shape how patents perform in practice. 

You Didn’t Build a Moat. You Built a Moment. 

AI has accelerated drug discovery, but it has also shortened the window of competitive advantage. This article explores why patent strategy must evolve beyond protecting individual molecules to safeguarding the platforms, data, and infrastructure that create long-term business value.

Read More

You Built the AI. So Why Don’t You Own the Drug? 

Owning a patented molecule does not necessarily mean owning the innovation behind it. As AI transforms drug discovery, companies must understand how data, platforms, collaborations, and IP agreements shape long-term ownership, commercialization, and competitive advantage.

Read More

AI Is Speeding Up Drug Discovery. Your IP Strategy Is Still Moving at Yesterday’s Pace

AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.

Read More

HOW LIFE SCIENCES INNOVATORS ARE PROTECTING VALUE AS THE PATENT CLIFF LOOMS

As blockbuster drugs approach patent expiration, life sciences companies face significant revenue risk. Strategic patent portfolio management, validity analysis, and innovation planning can help organizations protect value and maintain competitive advantage beyond loss of exclusivity.

Read More

Hylton-Rodic Law | Q1 2026

As innovation accelerates, life sciences companies must align patent strategy with long-term growth. This update explores how portfolio design, operational structure, and early IP decisions shape flexibility, commercialization, and long-term value.

Read More